BMND8
MCID: BNM022
MIFTS: 45

Bone Mineral Density Quantitative Trait Locus 8 (BMND8)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 8

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 8:

Name: Bone Mineral Density Quantitative Trait Locus 8 57
Osteoporosis, Susceptibility to 57 6
Osteoporosis 57 70
Bmnd8 57

Classifications:



External Ids:

OMIM® 57 611739
UMLS 70 C0029456

Summaries for Bone Mineral Density Quantitative Trait Locus 8

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 8, also known as osteoporosis, susceptibility to, is related to bone mineral density quantitative trait locus 15 and osteoporosis, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 8 is BMND8 (Bone Mineral Density Quantiative Trait Locus 8). The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and bone marrow.

Wikipedia : 73 Bone mineral density quantitative trait locus 8 is a protein that in humans is encoded by the BMND8... more...

More information from OMIM: 611739

Related Diseases for Bone Mineral Density Quantitative Trait Locus 8

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1091)
# Related Disease Score Top Affiliating Genes
1 bone mineral density quantitative trait locus 15 32.2 PDLIM4 CALCR
2 osteoporosis 31.9 PDLIM4 CALCR BMND8
3 osteoporosis, juvenile 11.8
4 osteoporosis-pseudoglioma syndrome 11.7
5 hajdu-cheney syndrome 11.5
6 glucocorticoid-induced osteoporosis 11.5
7 nephrolithiasis/osteoporosis, hypophosphatemic, 1 11.5
8 nephrolithiasis/osteoporosis, hypophosphatemic, 2 11.5
9 juvenile primary osteoporosis 11.5
10 osteoporosis and oculocutaneous hypopigmentation syndrome 11.3
11 hypophosphatemic nephrolithiasis/osteoporosis 11.3
12 bone mineral density quantitative trait locus 16 11.3
13 bone mineral density quantitative trait locus 18 11.2
14 bone disease 11.2
15 bone resorption disease 11.2
16 rickets 11.2
17 premature menopause 11.1
18 werner syndrome 11.1
19 syndromic x-linked intellectual disability snyder type 11.1
20 multicentric osteolysis, nodulosis, and arthropathy 11.1
21 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 11.1
22 hyperparathyroidism 11.1
23 aromatase deficiency 11.1
24 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 11.0
25 winchester syndrome 11.0
26 bone mineral density quantitative trait locus 12 11.0
27 lysinuric protein intolerance 11.0
28 geroderma osteodysplasticum 11.0
29 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.0
30 mucolipidosis iii alpha/beta 11.0
31 nestor-guillermo progeria syndrome 11.0
32 ehlers-danlos syndrome, classic-like, 2 11.0
33 hypogonadotropic hypogonadism 11.0
34 hyperthyroidism 11.0
35 anorexia nervosa 10.9
36 cerebrotendinous xanthomatosis 10.9
37 cholangitis, primary sclerosing 10.9
38 bone mineral density quantitative trait locus 3 10.9
39 celiac disease 1 10.9
40 mental retardation, x-linked, syndromic, snyder-robinson type 10.9
41 spondyloocular syndrome 10.9
42 cleidocranial dysplasia 10.9
43 acth-secreting pituitary adenoma 10.9
44 cutis laxa osteoporosis 10.9
45 systemic mastocytosis 10.9
46 hyperparathyroidism 1 10.9
47 dyskeratosis congenita, autosomal recessive 1 10.9
48 hyaline fibromatosis syndrome 10.9
49 mucolipidosis iii gamma 10.9
50 prader-willi habitus, osteopenia, and camptodactyly 10.9

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 8:



Diseases related to Bone Mineral Density Quantitative Trait Locus 8

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 8

Clinical features from OMIM®:

611739 (Updated 20-May-2021)

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 8:


tremor; back pain; angina pectoris; sciatica; equilibration disorder; muscle cramp; pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 8

Drugs for Bone Mineral Density Quantitative Trait Locus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 377)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
9
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
10
Ribavirin Approved Phase 4 36791-04-5 37542
11
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
12
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
13
Gliclazide Approved Phase 4 21187-98-4 3475
14 Strontium ranelate Approved, Withdrawn Phase 4 135459-87-9
15
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
16
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
17
Atorvastatin Approved Phase 4 134523-00-5 60823
18
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
19
Racepinephrine Approved Phase 4 329-65-7 838
20
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
21
Pamidronate Approved Phase 4 40391-99-9 4674
22
Demeclocycline Approved Phase 4 127-33-3 5311063
23
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
24
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
25
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
26
Tibolone Approved, Investigational Phase 4 5630-53-5
27
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
28
Lactitol Approved, Investigational Phase 4 585-86-4 157355
29
Liraglutide Approved Phase 4 204656-20-2 44147092
30
Exemestane Approved, Investigational Phase 4 107868-30-4 60198
31
Abaloparatide Approved, Investigational Phase 4 247062-33-5
32
tannic acid Approved Phase 4 1401-55-4
33
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
34
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
35
Cinacalcet Approved Phase 4 226256-56-0 156419
36
Morphine Approved, Investigational Phase 4 57-27-2 5288826
37
Ibuprofen Approved Phase 4 15687-27-1 3672
38
Acetaminophen Approved Phase 4 103-90-2 1983
39
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
40
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
41
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
42
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
43
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
44
Zoledronic Acid Approved Phase 4 118072-93-8 68740
45
Pravastatin Approved Phase 4 81093-37-0 54687
46
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
47
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
49
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4 53-43-0 5881
50
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205

Interventional clinical trials:

(show top 50) (show all 1349)
# Name Status NCT ID Phase Drugs
1 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
2 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Unknown status NCT03926377 Phase 4
3 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
4 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
5 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
6 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Unknown status NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
7 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
8 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
9 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
10 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
11 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
12 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
13 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
14 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
15 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
16 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
17 Fracture (FX) Improvement With Teriparatide: FiX-IT Study Completed NCT01705587 Phase 4 teriparatide
18 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
19 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
20 Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study Completed NCT02808988 Phase 4
21 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
22 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
23 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
24 Antiepileptic Drugs and Osteoporotic Prevention Trial Completed NCT00869622 Phase 4 Risedronate;Placebo + Calcium and Vitamin D
25 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
26 OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study Completed NCT00592917 Phase 4
27 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
28 Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid
29 The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass Completed NCT02499237 Phase 4 Denosumab;Zoledronic acid
30 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
31 A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg) Completed NCT00327990 Phase 4 Ibandronate;Alendronate
32 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
33 Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study Completed NCT00371956 Phase 4 raloxifene;placebo
34 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients - A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
35 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
36 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
37 A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis. Completed NCT00545480 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
38 A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program Completed NCT00545363 Phase 4 Ibandronate
39 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
40 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
41 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
42 A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates Completed NCT01732770 Phase 4 Zoledronic Acid;Placebo to Denosumab;Placebo to Zoledronic Acid
43 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
44 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
45 Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis Completed NCT00632216 Phase 4 Risedronate Sodium
46 Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study Completed NCT00532428 Phase 4 Raloxifene;Raloxifene;Placebo
47 A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women Completed NCT00860964 Phase 4 Placebo;estradiol valerate
48 A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Completed NCT00503113 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva];Alendronate
49 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
50 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 8

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 8

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 8

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 8:

40
Bone, Prostate, Bone Marrow, Breast, Kidney, Spinal Cord, Thyroid

Publications for Bone Mineral Density Quantitative Trait Locus 8

Articles related to Bone Mineral Density Quantitative Trait Locus 8:

(show top 50) (show all 30004)
# Title Authors PMID Year
1
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 61 6
19920351 2009
2
Linkage to chromosome 11p12 in two Maltese families with a highly penetrant form of osteoporosis. 61 57
17377523 2007
3
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 6
12908099 2003
4
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 6
9817931 1998
5
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 6
9571205 1998
6
Allelic variants of human calcitonin receptor in the Japanese population. 6
9003491 1997
7
Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis. 61
33734011 2021
8
Ficus deltoidea promotes bone formation in streptozotocin-induced diabetic rats. 61
33399485 2021
9
Lithium chloride promotes osteogenesis and suppresses apoptosis during orthodontic tooth movement in osteoporotic model via regulating autophagy. 61
33778189 2021
10
Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab. 61
33506078 2021
11
Effect of ErhBMP-2-loaded β-tricalcium phosphate on ulna defects in the osteoporosis rabbit model. 61
33364265 2021
12
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis. 61
33665236 2021
13
Severe injury-induced osteoporosis and skeletal muscle mineralization: Are these related complications? 61
33490313 2021
14
3D‑printed Ti6Al4V scaffolds combined with pulse electromagnetic fields enhance osseointegration in osteoporosis. 61
33786622 2021
15
Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis. 61
32558699 2021
16
Quercetin and vitamin E alleviate ovariectomy-induced osteoporosis by modulating autophagy and apoptosis in rat bone cells. 61
33030247 2021
17
Osteoporosis and osteoblasts cocultured with adipocytes inhibit osteoblast differentiation by downregulating histone acetylation. 61
33124698 2021
18
Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis. 61
32862655 2021
19
Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. 61
33601146 2021
20
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid. 61
33135182 2021
21
Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations. 61
33618074 2021
22
Total glycosides and polysaccharides of Cistanche deserticola prevent osteoporosis by activating Wnt/β-catenin signaling pathway in SAMP6 mice. 61
33549763 2021
23
High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study. 61
33610904 2021
24
Longitudinal effects of low-intensity pulsed ultrasound on osteoporosis and osteoporotic bone defect in ovariectomized rats. 61
33561635 2021
25
Osteoporosis and fractures in rheumatoid arthritis. 61
33651725 2021
26
Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. 61
33382995 2021
27
Syndecan-3 enhances anabolic bone formation through WNT signaling. 61
33769615 2021
28
Osteogenic effects of the peptide fraction derived from pepsin-hydrolyzed bovine lactoferrin. 61
33551166 2021
29
The role of strontium ranelate and guided bone regeneration in osteoporotic and healthy conditions. 61
33368312 2021
30
Approaches to Fracture Risk Assessment and Prevention. 61
33523422 2021
31
Oxidative Stress-Induced Hypermethylation of KLF5 Promoter Mediated by DNMT3B Impairs Osteogenesis by Diminishing the Interaction with β-Catenin. 61
33588625 2021
32
Bone Mineral Density: Clinical Relevance and Quantitative Assessment. 61
33310738 2021
33
Biomechanical Evaluation of Oblique Lumbar Interbody Fusion with Various Fixation Options: A Finite Element Analysis. 61
33619850 2021
34
Agastache rugosa ethanol extract suppresses bone loss via induction of osteoblast differentiation with alteration of gut microbiota. 61
33626428 2021
35
The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis. 61
32914348 2021
36
By inhibiting ADCY5, miR-18a-3p promotes osteoporosis and possibly contributes to spinal fracture. 61
33684620 2021
37
Hydrophilic titanium surface modulates early stages of osseointegration in osteoporosis. 61
33368275 2021
38
In Silico Network Analysis of Ingredients of Cornus officinalis in Osteoporosis. 61
33795629 2021
39
Vertebral Collapse Prevented Following Teriparatide Treatment in Postmenopausal Kümmell's Disease Patients with Severe Osteoporosis. 61
33615746 2021
40
Oxidative stress induces downregulation of TP53INP2 and suppresses osteogenic differentiation of BMSCs during osteoporosis through the autophagy degradation pathway. 61
33636337 2021
41
[Osteoporosis-Update 2021]. 61
33780987 2021
42
Green tea extract synergistically enhances the effectiveness of an antiresorptive drug on management of osteoporosis induced by ovariectomy in a rat model. 61
33732301 2021
43
Long-term evaluation of anabolic and anti-resorptive agents in adults with familial osteoporosis due to pro205ala variant of the col1a1 gene. 61
33796912 2021
44
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose? 61
33635520 2021
45
Opportunistic osteoporosis screening in multi-detector CT images using deep convolutional neural networks. 61
33001308 2021
46
Circ-ITCH sponges miR-214 to promote the osteogenic differentiation in osteoporosis via upregulating YAP1. 61
33795657 2021
47
Bone densitometry categories as a salient distracting feature in the modern clinical pathways of osteoporosis care: A retrospective 20-year cohort study. 61
33484888 2021
48
Mineral and organic matrix composition at bone forming surfaces in postmenopausal women with osteoporosis treated with either teriparatide or zoledronic acid. 61
33453443 2021
49
Osteoporosis in Adult Patients with Intellectual and Developmental Disabilities: Special Considerations for Diagnosis, Prevention, and Management. 61
33787940 2021
50
Clinical guidelines for the application of panoramic radiographs in screening for osteoporosis. 61
33620644 2021

Variations for Bone Mineral Density Quantitative Trait Locus 8

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 8:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LOC113839511 , MIR2861 NR_036055.1(MIR2861):n.33C>G SNV association 106 rs794728003 GRCh37: 9:130548229-130548229
GRCh38: 9:127785950-127785950
2 PDLIM4 RIL, -3333T-C SNV risk factor 6348 GRCh37:
GRCh38:
3 CALCR NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro) SNV risk factor 17636 rs1801197 GRCh37: 7:93055753-93055753
GRCh38: 7:93426441-93426441

Expression for Bone Mineral Density Quantitative Trait Locus 8

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 8.

Pathways for Bone Mineral Density Quantitative Trait Locus 8

GO Terms for Bone Mineral Density Quantitative Trait Locus 8

Sources for Bone Mineral Density Quantitative Trait Locus 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....